JAK inhibitors and immune system: Comparison
Please note this is a comparison between Version 2 by Conner Chen and Version 1 by Agnieszka Witalisz-Siepracka.

The Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway is aberrantly activated in many malignancies. Inhibition of this pathway via JAK inhibitors (JAKinibs) is therefore an attractive therapeutic strategy underlined by Ruxolitinib (JAK1/2 inhibitor) being approved for the treatment of myeloproliferative neoplasms. As a consequence of the crucial role of the JAK-STAT pathway in the regulation of immune responses, inhibition of JAKs suppresses the immune system. This review article provides a thorough overview of the current knowledge on JAKinibs’ effects on immune cells in the context of hematological malignancies. We also discuss the potential use of JAKinibs for the treatment of diseases in which lymphocytes are the source of the malignancy.

  • JAK
  • STAT
  • JAK inhibitor
  • leukemia
  • NK cells
  • T cells
Please wait, diff process is still running!

References

  1. Schindler, C.; Levy, D.E.; Decker, T. JAK-STAT Signaling: From Interferons to Cytokines. J. Biol. Chem. 2007, 282, 20059–20063.
  2. O’Shea, J.J.; Plenge, R. JAK and STAT Signaling Molecules in Immunoregulation and Immune-Mediated Disease. Immunity 2012, 36, 542–550.
  3. Stark, G.R.; Darnell, J.E., Jr. The JAK-STAT Pathway at Twenty. Immunity 2012, 36, 503–514.
  4. Hammarén, H.M.; Virtanen, A.T.; Raivola, J.; Silvennoinen, O. The regulation of JAKs in cytokine signaling and its breakdown in disease. Cytokine 2019, 118, 48–63.
  5. Villarino, A.V.; Kanno, Y.; O’Shea, A.V.V.Y.K.J.J. Mechanisms and consequences of Jak–STAT signaling in the immune system. Nat. Immunol. 2017, 18, 374–384.
  6. Levy, D.E.; Darnell, J.E., Jr. STATs: Transcriptional control and biological impact. Nat. Rev. Mol. Cell Biol. 2002, 3, 651–662.
  7. Shuai, K.; Liu, B. Regulation of JAK–STAT signalling in the immune system. Nat. Rev. Immunol. 2003, 3, 900–911.
  8. Kiu, H.; Nicholson, S.E. Biology and significance of the JAK/STAT signalling pathways. Growth Factors 2012, 30, 88–106.
  9. Morris, R.; Kershaw, N.J.; Babon, J.J. The molecular details of cytokine signaling via the JAK/STAT pathway. Protein Sci. 2018, 27, 1984–2009.
  10. Villarino, A.; Kanno, Y.; Ferdinand, J.R.; O’Shea, J.J. Mechanisms of Jak/STAT Signaling in Immunity and Disease. J. Immunol. 2015, 194, 21–27.
  11. McLornan, D.P.; Khan, A.A.; Harrison, C.N. Immunological Consequences of JAK Inhibition: Friend or Foe? Curr. Hematol. Malign- Rep. 2015, 10, 370–379.
  12. Gadina, M.; Johnson, C.; Schwartz, D.; Bonelli, M.; Hasni, S.; Kanno, Y.; Changelian, P.; Laurence, A.; O’Shea, J.J. Translational and clinical advances in JAK-STAT biology: The present and future of jakinibs. J. Leukoc. Biol. 2018, 104, 499–514.
  13. Casanova, J.-L.; Holland, S.M.; Notarangelo, L.D. Inborn Errors of Human JAKs and STATs. Immunity 2012, 36, 515–528.
  14. O’Shea, J.J.; Holland, S.M.; Staudt, L.M. JAKs and STATs in Immunity, Immunodeficiency, and Cancer. New Engl. J. Med. 2013, 368, 161–170.
  15. Senkevitch, E.; Durum, S. The promise of Janus kinase inhibitors in the treatment of hematological malignancies. Cytokine 2017, 98, 33–41.
  16. Schwartz, D.M.; Kanno, Y.; Villarino, A.; Ward, M.; Gadina, M.; O’Shea, J.J. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat. Rev. Drug Discov. 2017, 16, 843–862.
  17. Chen, E.; Staudt, L.M.; Green, A.R. Janus Kinase Deregulation in Leukemia and Lymphoma. Immunity 2012, 36, 529–541.
  18. Thomas, S.J.; Snowden, J.A.; Zeidler, M.; Danson, S. The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours. Br. J. Cancer 2015, 113, 365–371.
  19. Igelmann, S.; Neubauer, H.A.; Ferbeyre, G. STAT3 and STAT5 Activation in Solid Cancers. Cancers 2019, 11, 1428.
  20. Saharinen, P.; Takaluoma, K.; Silvennoinen, O. Regulation of the Jak2 Tyrosine Kinase by Its Pseudokinase Domain. Mol. Cell. Biol. 2000, 20, 3387–3395.
  21. Saharinen, P.; Vihinen, M.; Silvennoinen, O. Autoinhibition of Jak2 Tyrosine Kinase Is Dependent on Specific Regions in Its Pseudokinase Domain. Mol. Biol. Cell 2003, 14, 1448–1459.
  22. Toms, A.V.; Deshpande, A.; McNally, R.; Jeong, Y.; Rogers, J.M.; Kim, C.U.; Gruner, S.M.; Ficarro, S.B.; A Marto, J.; Sattler, M.; et al. Structure of a pseudokinase-domain switch that controls oncogenic activation of Jak kinases. Nat. Struct. Mol. Biol. 2013, 20, 1221–1223.
  23. Lupardus, P.J.; Ultsch, M.; Wallweber, H.; Kohli, P.B.; Johnson, A.R.; Eigenbrot, C. Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition. Proc. Natl. Acad. Sci. 2014, 111, 8025–8030.
  24. Ferrao, R.; Lupardus, P.J. The Janus Kinase (JAK) FERM and SH2 Domains: Bringing Specificity to JAK–Receptor Interactions. Front. Endocrinol. 2017, 8, 71.
  25. Staerk, J.; Kallin, A.; Demoulin, J.-B.; Vainchenker, W.; Constantinescu, S.N. JAK1 and Tyk2 Activation by the Homologous Polycythemia Vera JAK2 V617F Mutation. J. Biol. Chem. 2005, 280, 41893–41899.
  26. Baxter, E.J.; Scott, L.M.; Campbell, P.J.; East, C.; Fourouclas, N.; Swanton, S.; Vassiliou, G.; Bench, A.J.; Boyd, E.M.; Curtin, N.; et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005, 365, 1054–1061.
  27. E James, C.; Ugo, V.; Le Couédic, J.-P.; Staerk, J.; Delhommeau, F.; Lacout, C.; Garçon, L.; Raslova, H.; Berger, R.; Bennaceur-Griscelli, A.; et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nat. Cell Biol. 2005, 434, 1144–1148.
  28. Kralovics, R.; Passamonti, F.; Buser, A.S.; Teo, S.-S.; Tiedt, R.; Passweg, J.R.; Tichelli, A.; Cazzola, M.; Skoda, R.C. A Gain-of-Function Mutation ofJAK2in Myeloproliferative Disorders. New Engl. J. Med. 2005, 352, 1779–1790.
  29. Lee, J.W.; Kim, Y.G.; Soung, Y.H.; Han, K.J.; Kim, S.Y.; Rhim, H.; Min, W.S.; Nam, S.W.; Park, W.S.; Yoo, N.J.; et al. The JAK2 V617F mutation in de novo acute myelogenous leukemias. Oncogene 2005, 25, 1434–1436.
  30. Passamonti, F.; Rumi, E.; Pietra, D.; Della Porta, M.G.; Boveri, E.; Pascutto, C.; Vanelli, L.; Arcaini, L.; Burcheri, S.; Malcovati, L.; et al. Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. Blood 2006, 107, 3676–3682.
  31. Mascarenhas, J.; Hoffman, R. Ruxolitinib: The First FDA Approved Therapy for the Treatment of Myelofibrosis: Figure 1. Clin. Cancer Res. 2012, 18, 3008–3014.
  32. Vainchenker, W.; Constantinescu, S. JAK/STAT signaling in hematological malignancies. Oncogene 2012, 32, 2601–2613.
  33. Raedler, L.A. Jakafi (Ruxolitinib): First FDA-Approved Medication for the Treatment of Patients with Polycythemia Vera. Am. Health Drug benefits 2015, 8, 75–79.
  34. Skoda, R.C.; Duek, A.; Grisouard, J. Pathogenesis of myeloproliferative neoplasms. Exp. Hematol. 2015, 43, 599–608.
  35. De Noronha, T.R.; Mitne-Neto, M.; Chauffaille, M.D.L. JAK2-mutated acute myeloid leukemia: Comparison of next-generation sequencing (NGS) and single nucleotide polymorphism array (SNPa) findings between two cases. Autops. Case Rep. 2019, 9, e2018084.
  36. Mead, A.J.; Rugless, M.J.; Jacobsen, S.E.W.; Schuh, A. GermlineJAK2Mutation in a Family with Hereditary Thrombocytosis. New Engl. J. Med. 2012, 366, 967–969.
  37. Etheridge, S.L.; Cosgrove, M.E.; Sangkhae, V.; Corbo, L.M.; Roh, M.E.; Seeliger, M.A.; Chan, E.L.; Hitchcock, I.S. A novel activating, germline JAK2 mutation, JAK2R564Q, causes familial essential thrombocytosis. Blood 2014, 123, 1059–1068.
  38. Marty, C.; Saint-Martin, C.; Pecquet, C.; Grosjean, S.; Saliba, J.; Mouton, C.; Leroy, E.; Harutyunyan, A.S.; Abgrall, J.-F.; Favier, R.; et al. Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors. Blood 2014, 123, 1372–1383.
  39. Jeong, E.G.; Kim, M.S.; Nam, H.K.; Min, C.K.; Lee, S.; Chung, Y.J.; Yoo, N.J.; Lee, S.H. Somatic Mutations of JAK1 and JAK3 in Acute Leukemias and Solid Cancers. Clin. Cancer Res. 2008, 14, 3716–3721.
  40. Mullighan, C.G.; Zhang, J.; Harvey, R.C.; Collins-Underwood, J.R.; Schulman, B.A.; Phillips, L.A.; Tasian, S.K.; Loh, M.L.; Su, X.; Liu, W.; et al. JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc. Natl. Acad. Sci. 2009, 106, 9414–9418.
  41. Bellanger, D.E.; Jacquemin, V.; Chopin, M.; Pierron, G.; A Bernard, O.; Ghysdael, J.; Stern, M.-H. Recurrent JAK1 and JAK3 somatic mutations in T-cell prolymphocytic leukemia. Leukemia 2014, 28, 417–419.
  42. Arulogun, S.O.; Choong, H.-L.; Taylor, D.; Ambrosoli, P.; Magor, G.; Irving, I.M.; Keng, T.-B.; Perkins, A.C. JAK1 somatic mutation in a myeloproliferative neoplasm. Haematologica 2017, 102, e324–e327.
  43. Lee, S.; Park, H.Y.; Kang, S.Y.; Kim, S.J.; Hwang, J.; Lee, S.; Kwak, S.H.; Park, K.S.; Yoo, H.Y.; Kim, W.S.; et al. Genetic alterations of JAK/STAT cascade and histone modification in extranodal NK/T-cell lymphoma nasal type. Oncotarget 2015, 6, 17764–17776.
  44. Ross, J.A.; Kirken, R.A. Transforming Mutations of Jak3 (A573V and M511I) Show Differential Sensitivity to Selective Jak3 Inhibitors. Clin. Cancer Drugs 2016, 3, 131–137.
  45. Sim, S.H.; Kim, S.; Kim, T.M.; Jeon, Y.K.; Nam, S.J.; Ahn, Y.-O.; Keam, B.; Park, H.H.; Kim, D.-W.; Kim, C.W.; et al. Novel JAK3-Activating Mutations in Extranodal NK/T-Cell Lymphoma, Nasal Type. Am. J. Pathol. 2017, 187, 980–986.
  46. Kiyoi, H.; Yamaji, S.; Kojima, S.; Naoe, T. JAK3 mutations occur in acute megakaryoblastic leukemia both in Down syndrome children and non-Down syndrome adults. Leukemia 2007, 21, 574–576.
  47. Malinge, S.; Ragu, C.; Della-Valle, V.; Pisani, D.; Constantinescu, S.N.; Perez, C.; Villeval, J.-L.; Reinhardt, D.; Landman-Parker, J.; Michaux, L.; et al. Activating mutations in human acute megakaryoblastic leukemia. Blood 2008, 112, 4220–4226.
  48. Yamashita, Y.; Yuan, J.; Suetake, I.; Suzuki, H.; Ishikawa, Y.; Choi, Y.L.; Ueno, T.; Soda, M.; Hamada, T.; Haruta, H.; et al. Array-based genomic resequencing of human leukemia. Oncogene 2010, 29, 3723–3731.
  49. Bains, T.; Heinrich, M.C.; Loriaux, M.M.; Beadling, C.; Nelson, D.; Warrick, A.; Neff, T.L.; Tyner, J.W.; Dunlap, J.; Corless, C.L.; et al. Newly described activating JAK3 mutations in T-cell acute lymphoblastic leukemia. Leukemia 2012, 26, 2144–2146.
  50. Koo, G.C.; Tan, S.Y.; Tang, T.; Poon, S.L.; Allen, G.E.; Tan, L.; Chong, S.C.; Ong, W.S.; Tay, K.; Tao, M.; et al. Janus Kinase 3–Activating Mutations Identified in Natural Killer/T-cell Lymphoma. Cancer Discov. 2012, 2, 591–597.
  51. Zhang, J.; Ding, L.; Holmfeldt, L.; Wu, G.; Heatley, S.L.; Payne-Turner, D.; Easton, J.; Chen, X.; Wang, J.; Rusch, M.; et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 2012, 481, 157–163.
  52. Bergmann, A.K.; Schneppenheim, S.; Seifert, M.; Betts, M.J.; Haake, A.; Lopez, C.; Penas, E.M.M.; Vater, I.; Jayne, S.; Dyer, M.J.; et al. Recurrent mutation ofJAK3in T-cell prolymphocytic leukemia. Genes, Chromosom. Cancer 2014, 53, 309–316.
  53. Bouchekioua, A.; Scourzic, L.; De Wever, O.; Zhang, Y.; Cervera, P.; Aline-Fardin, A.; Mercher, T.; Gaulard, P.; Nyga, R.; Jeziorowska, D.; et al. JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma. Leukemia 2014, 28, 338–348.
  54. Sanda, T.; Tyner, J.W.; Gutierrez, A.; Ngo, V.N.; Glover, J.; Chang, B.H.; Yost, A.; Ma, W.; Fleischman, A.; Zhou, W.; et al. TYK2–STAT1–BCL2 Pathway Dependence in T-cell Acute Lymphoblastic Leukemia. Cancer Discov. 2013, 3, 564–577.
  55. Waanders, E.; Scheijen, B.; Jongmans, M.; Venselaar, H.; Van Reijmersdal, S.; Van Dijk, A.; Pastorczak, A.; Weren, R.; Van Der Schoot, C.; Van De Vorst, J.; et al. Germline activating TYK2 mutations in pediatric patients with two primary acute lymphoblastic leukemia occurrences. Leukemia 2017, 31, 821–828.
  56. Wöss, K.; Simonović, N.; Strobl, B.; Macho-Maschler, S.; Müller, M. TYK2: An Upstream Kinase of STATs in Cancer. Cancers 2019, 11, 1728.
  57. Scott, L.M. The JAK2 exon 12 mutations: A comprehensive review. Am. J. Hematol. 2011, 86, 668–676.
  58. Blombery, P.; Thompson, E.R.; Jones, K.; Arnau, G.M.; Lade, S.; Markham, J.F.; Li, J.; Deva, A.; Johnstone, R.W.; Khot, A.; et al. Whole exome sequencing reveals activating JAK1 and STAT3 mutations in breast implant-associated anaplastic large cell lymphoma anaplastic large cell lymphoma. Haematologica 2016, 101, e387–e390.
  59. Li, Q.; Li, B.; Hu, L.; Ning, H.; Jiang, M.; Wang, D.; Liu, T.; Zhang, B.; Chen, H. Identification of a novel functional JAK1 S646P mutation in acute lymphoblastic leukemia. Oncotarget 2017, 8, 34687–34697.
  60. Flex, E.; Petrangeli, V.; Stella, L.; Chiaretti, S.; Hornakova, T.; Knoops, L.; Ariola, C.; Fodale, V.; Clappier, E.; Paoloni, F.; et al. Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. J. Exp. Med. 2008, 205, 751–758.
  61. Hornakova, T.; Springuel, L.; Devreux, J.; Dusa, A.; Constantinescu, S.N.; Knoops, L.; Renauld, J.-C. Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors. Haematologica 2011, 96, 845–853.
  62. Crescenzo, R.; Abate, F.; Lasorsa, E.; Tabbo’, F.; Gaudiano, M.; Chiesa, N.; Di Giacomo, F.; Spaccarotella, E.; Barbarossa, L.; Ercole, E.; et al. Convergent Mutations and Kinase Fusions Lead to Oncogenic STAT3 Activation in Anaplastic Large Cell Lymphoma. Cancer Cell 2015, 27, 516–532.
  63. Lesmana, H.; Popescu, M.; Lewis, S.; Sahoo, S.S.; Goodings-Harris, C.; Onciu, M.; Choi, J.K.; Takemoto, C.; Nichols, K.E.; Wlodarski, M. Germline Gain-of-Function JAK3 Mutation in Familial Chronic Lymphoproliferative Disorder of NK Cells. Blood 2020, 136, 9–10.
  64. Klusmann, J.-H.; Reinhardt, D.; Hasle, H.; Kaspers, G.J.; Creutzig, U.; Hählen, K.; Heuvel-Eibrink, M.M.V.D.; Zwaan, C.M. Janus kinase mutations in the development of acute megakaryoblastic leukemia in children with and without Down’s syndrome. Leukemia 2007, 21, 1584–1587.
  65. Elliott, N.E.; Cleveland, S.M.; Grann, V.; Janik, J.; Waldmann, T.A.; Davé, U.P. FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma. Blood 2011, 118, 3911–3921.
  66. Degryse, S.; De Bock, C.E.; Cox, L.; Demeyer, S.; Gielen, O.; Mentens, N.; Jacobs, K.; Geerdens, E.; Gianfelici, V.; Hulselmans, G.; et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood 2014, 124, 3092–3100.
  67. Haapaniemi, E.M.; Kaustio, M.; Rajala, H.L.M.; Van Adrichem, A.J.; Kainulainen, L.; Glumoff, V.; Doffinger, R.; Kuusanmäki, H.; Heiskanen-Kosma, T.; Trotta, L.; et al. Autoimmunity, hypogammaglobulinemia, lymphoproliferation, and mycobacterial disease in patients with activating mutations in STAT3. Blood 2015, 125, 639–648.
  68. Shahmarvand, N.; Nagy, A.; Shahryari, J.; Ohgami, R.S. Mutations in the signal transducer and activator of transcription family of genes in cancer. Cancer Sci. 2018, 109, 926–933.
  69. De Araujo, E.D.; Orlova, A.; Neubauer, H.A.; Bajusz, D.; Seo, H.-S.; Dhe-Paganon, S.; Keserű, G.M.; Moriggl, R.; Gunning, P.T. Structural Implications of STAT3 and STAT5 SH2 Domain Mutations. Cancers 2019, 11, 1757.
  70. Hu, G.; Witzig, T.E.; Gupta, M. A Novel Missense (M206K) STAT3 Mutation in Diffuse Large B Cell Lymphoma Deregulates STAT3 Signaling. PLoS ONE 2013, 8, e67851.
  71. Andersson, E.; Kuusanmäki, H.; Bortoluzzi, S.; Lagström, S.; Parsons, A.; Rajala, H.; Van Adrichem, A.; Eldfors, S.; Olson, T.; Clemente, M.J.; et al. Activating somatic mutations outside the SH2-domain of STAT3 in LGL leukemia. Leukemia 2015, 30, 1204–1208.
  72. Jerez, A.; Clemente, M.J.; Makishima, H.; Koskela, H.; Leblanc, F.; Ng, K.P.; Olson, T.; Przychodzen, B.; Afable, M.; Gomez-Segui, I.; et al. STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. Blood 2012, 120, 3048–3057.
  73. Koskela, H.L.; Eldfors, S.; Ellonen, P.; Van Adrichem, A.J.; Kuusanmäki, H.; Andersson, E.I.; Lagström, S.; Clemente, M.J.; Olson, T.; Jalkanen, S.E.; et al. SomaticSTAT3Mutations in Large Granular Lymphocytic Leukemia. New Engl. J. Med. 2012, 366, 1905–1913.
  74. Fasan, A.; Kern, W.; Grossmann, V.; Haferlach, C.; Schnittger, S.; Haferlach, T. STAT3 mutations are highly specific for large granular lymphocytic leukemia. Leukemia 2012, 27, 1598–1600.
  75. Küçük, C.; Jiang, B.; Hu, X.; Zhang, W.; Chan, J.K.C.; Xiao, W.; Lack, N.; Alkan, C.; Williams, J.C.; Avery, K.N.; et al. Activating mutations of STAT5B and STAT3 in lymphomas derived from γδ-T or NK cells. Nat. Commun. 2015, 6, 1–12.
  76. Bilori, B.; Thota, S.; Clemente, M.J.; Patel, B.; Jerez, A.; Ii, M.A.; Maciejewski, J.P. Tofacitinib as a novel salvage therapy for refractory T-cell large granular lymphocytic leukemia. Leukemia 2015, 29, 2427–2429.
  77. Kuusanmäki, H.; Dufva, O.; Parri, E.; Van Adrichem, A.J.; Rajala, H.; Majumder, M.M.; Yadav, B.; Parsons, A.; Chan, W.C.; Wennerberg, K.; et al. Drug sensitivity profiling identifies potential therapies for lymphoproliferative disorders with overactive JAK/STAT3 signaling. Oncotarget 2017, 8, 97516–97527.
  78. Matutes, E. The 2017 WHO update on mature T- and natural killer (NK) cell neoplasms. Int. J. Lab. Hematol. 2018, 40, 97–103.
  79. De Araujo, E.D.; Erdogan, F.; Neubauer, H.A.; Meneksedag-Erol, D.; Manaswiyoungkul, P.; Eram, M.S.; Seo, H.-S.; Qadree, A.K.; Israelian, J.; Orlova, A.; et al. Structural and functional consequences of the STAT5BN642H driver mutation. Nat. Commun. 2019, 10, 1–15.
  80. Pham, H.T.T.; Maurer, B.; Prchal-Murphy, M.; Grausenburger, R.; Grundschober, E.; Javaheri, T.; Nivarthi, H.; Boersma, A.; Kolbe, T.; Elabd, M.; et al. STAT5BN642H is a driver mutation for T cell neoplasia. J. Clin. Investig. 2017, 128, 387–401.
  81. Klein, K.; Witalisz-Siepracka, A.; Maurer, B.; Prinz, D.; Heller, G.; Leidenfrost, N.; Prchal-Murphy, M.; Suske, T.; Moriggl, R.; Sexl, V. STAT5BN642H drives transformation of NKT cells: A novel mouse model for CD56+ T-LGL leukemia. Leukemia 2019, 33, 2336–2340.
  82. Nicolae, A.; Xi, L.; Pittaluga, S.; Abdullaev, Z.; Pack, S.D.; Chen, J.; A Waldmann, T.; Jaffe, E.S.; Raffeld, M. Frequent STAT5B mutations in γδ hepatosplenic T-cell lymphomas. Leukemia 2014, 28, 2244–2248.
  83. Babushok, D.V.; Perdigones, N.; Perin, J.C.; Olson, T.S.; Ye, W.; Roth, J.J.; Lind, C.; Cattier, C.; Li, Y.; Hartung, H.; et al. Emergence of clonal hematopoiesis in the majority of patients with acquired aplastic anemia. Cancer Genet. 2015, 208, 115–128.
  84. Jiang, L.; Gu, Z.-H.; Yan, Z.-X.; Zhao, X.; Xie, Y.-Y.; Zhang, Z.-G.; Pan, C.-M.; Hu, Y.; Cai, C.-P.; Dong, Y.; et al. Exome sequencing identifies somatic mutations of DDX3X in natural killer/T-cell lymphoma. Nat. Genet. 2015, 47, 1061–1066.
  85. Kiel, M.J.; Velusamy, T.; Rolland, D.; Sahasrabuddhe, A.; Chung, F.; Bailey, N.G.; Schrader, A.; Li, B.; Li, J.Z.; Ozel, A.B.; et al. Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia. Blood 2014, 124, 1460–1472.
  86. Kiel, M.J.; Sahasrabuddhe, A.A.; Rolland, D.C.M.; Velusamy, T.; Chung, F.; Schaller, M.; Bailey, N.G.; Betz, B.L.; Miranda, R.N.; Porcu, P.; et al. Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK–STAT pathway in Sézary syndrome. Nat. Commun. 2015, 6, 8470.
  87. Ma, X.; Wen, L.; Wu, L.; Wang, Q.; Yao, H.; Wang, Q.; Ma, L.; Chen, S. Rare occurrence of a STAT5B N642H mutation in adult T-cell acute lymphoblastic leukemia. Cancer Genet. 2015, 208, 52–53.
  88. Andersson, E.I.; Tanahashi, T.; Sekiguchi, N.; Gasparini, V.R.; Bortoluzzi, S.; Kawakami, T.; Matsuda, K.; Mitsui, T.; Eldfors, S.; Bortoluzzi, S.; et al. High incidence of activating STAT5B mutations in CD4-positive T-cell large granular lymphocyte leukemia. Blood 2016, 128, 2465–2468.
  89. Nairismägi, M.-L.; Tan, J.; Lim, J.Q.; Nagarajan, S.; Ng, C.C.Y.; Rajasegaran, V.; Huang, D.; Lim, W.K.; Laurensia, Y.; Wijaya, G.C.; et al. JAK-STAT and G-protein-coupled receptor signaling pathways are frequently altered in epitheliotropic intestinal T-cell lymphoma. Leukemia 2016, 30, 1311–1319.
  90. Gao, L.-M.; Zhao, S.; Liu, W.-P.; Zhang, W.-Y.; Li, G.-D.; Küçük, C.; Hu, X.-Z.; Chan, W.C.; Tang, Y.; Ding, W.-S.; et al. Clinicopathologic Characterization of Aggressive Natural Killer Cell Leukemia Involving Different Tissue Sites. Am. J. Surg. Pathol. 2016, 40, 836–846.
  91. Teramo, A.; Barilà, G.; Calabretto, G.; Ercolin, C.; Lamy, T.; Moignet, A.; Roussel, M.; Pastoret, C.; Leoncin, M.; Gattazzo, C.; et al. STAT3 mutation impacts biological and clinical features of T-LGL leukemia. Oncotarget 2017, 8, 61876–61889.
  92. Ma, C.A.; Xi, L.; Cauff, B.; DeZure, A.; Freeman, A.F.; Hambleton, S.; Kleiner, G.; Leahy, T.R.; O’Sullivan, M.; Makiya, M.; et al. Somatic STAT5b gain-of-function mutations in early onset nonclonal eosinophilia, urticaria, dermatitis, and diarrhea. Blood 2017, 129, 650–653.
  93. Dufva, O.; Kankainen, M.; Kelkka, T.; Sekiguchi, N.; Awad, S.A.; Eldfors, S.; Yadav, B.; Kuusanmäki, H.; Malani, D.; I Andersson, E.; et al. Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target. Nat. Commun. 2018, 9, 1–12.
  94. Luo, Q.; Shen, J.; Yang, Y.; Tang, H.; Shi, M.; Liu, J.; Liu, Z.; Shi, X.; Yi, Y. CSF3RT618I,ASXL1G942 fs andSTAT5BN642H trimutation co-contribute to a rare chronic neutrophilic leukaemia manifested by rapidly progressive leucocytosis, severe infections, persistent fever and deep venous thrombosis. Br. J. Haematol. 2016, 180, 892–894.
  95. Huang, L.; Liu, D.; Wang, N.; Ling, S.; Tang, Y.; Wu, J.; Hao, L.; Luo, H.; Hu, X.; Sheng, L.; et al. Integrated genomic analysis identifies deregulated JAK/STAT-MYC-biosynthesis axis in aggressive NK-cell leukemia. Cell Res. 2017, 28, 172–186.
  96. Song, T.L.; Nairismägi, M.-L.; Laurensia, Y.; Lim, J.-Q.; Tan, J.; Li, Z.-M.; Pang, W.-L.; Kizhakeyil, A.; Wijaya, G.-C.; Huang, D.; et al. Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma. Blood 2018, 132, 1146–1158.
  97. Cross, N.C.P.; Hoade, Y.; Tapper, W.J.; Carreno-Tarragona, G.; Fanelli, T.; Jawhar, M.; Naumann, N.; Pieniak, I.; Lübke, J.; Ali, S.; et al. Recurrent activating STAT5B N642H mutation in myeloid neoplasms with eosinophilia. Leukemia 2018, 33, 415–425.
  98. Govaerts, I.; Jacobs, K.; Vandepoel, R.; Cools, J. JAK/STAT Pathway Mutations in T-ALL, Including the STAT5B N642H Mutation, are Sensitive to JAK1/JAK3 Inhibitors. HemaSphere 2019, 3, e313.
  99. Rajala, H.L.M.; Porkka, K.; Maciejewski, J.P.; Loughran, T.P.; Mustjoki, S. Uncovering the pathogenesis of large granular lymphocytic leukemia—novel STAT3 and STAT5b mutations. Ann. Med. 2014, 46, 114–122.
  100. Rajala, H.L.M.; Eldfors, S.; Kuusanmäki, H.; Van Adrichem, A.J.; Olson, T.; Lagström, S.; Andersson, E.I.; Jerez, A.; Clemente, M.J.; Yan, Y.; et al. Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia. Blood 2013, 121, 4541–4550.
  101. Bandapalli, O.R.; Schuessele, S.; Kunz, J.B.; Rausch, T.; Stütz, A.M.; Tal, N.; Geron, I.; Gershman, N.; Izraeli, S.; Eilers, J.; et al. The activating STAT5B N642H mutation is a common abnormality in pediatric T-cell acute lymphoblastic leukemia and confers a higher risk of relapse. Haematologica 2014, 99, e188–e192.
  102. Kontro, M.; Kuusanmäki, H.; Eldfors, S.; Burmeister, T.; Andersson, E.I.; Bruserud, O.; Brümmendorf, T.H.; Edgren, H.; Gjertsen, B.T.; Italaremes, M.; et al. Novel activating STAT5B mutations as putative drivers of T-cell acute lymphoblastic leukemia. Leukemia 2014, 28, 1738–1742.
  103. Ritz, O.; Guiter, C.; Castellano, F.; Dorsch, K.; Melzner, J.; Jais, J.-P.; Dubois, G.; Gaulard, P.; Möller, P.; Leroy, K. Recurrent mutations of the STAT6 DNA binding domain in primary mediastinal B-cell lymphoma. Blood 2009, 114, 1236–1242.
  104. Yildiz, M.; Li, H.; Bernard, D.; Amin, N.A.; Ouillette, P.; Jones, S.; Saiya-Cork, K.; Parkin, B.; Jacobi, K.; Shedden, K.; et al. Activating STAT6 mutations in follicular lymphoma. Blood 2015, 125, 668–679.
  105. Morin, R.D.; Assouline, S.; Alcaide, M.; Mohajeri, A.; Johnston, R.L.; Chong, L.; Grewal, J.; Yu, S.; Fornika, D.; Bushell, K.; et al. Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas. Clin. Cancer Res. 2016, 22, 2290–2300.
  106. Tiacci, E.; Ladewig, E.; Schiavoni, G.; Penson, A.; Fortini, E.; Pettirossi, V.; Wang, Y.; Rosseto, A.; Venanzi, A.; Vlasevska, S.; et al. Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma. Blood 2018, 131, 2454–2465.
  107. O’Shea, J.J.; Schwartz, D.M.; Villarino, A.; Gadina, M.; McInnes, I.B.; Laurence, A. The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention. Annu. Rev. Med. 2015, 66, 311–328.
  108. Levine, R.L.; Wadleigh, M.; Cools, J.; Ebert, B.L.; Wernig, G.; Huntly, B.J.; Boggon, T.J.; Wlodarska, I.; Clark, J.J.; Moore, S.; et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005, 7, 387–397.
  109. Helbig, G. Classical Philadelphia-negative myeloproliferative neoplasms: Focus on mutations and JAK2 inhibitors. Med Oncol. 2018, 35, 119.
  110. Lorenzini, T.; Dotta, L.; Giacomelli, M.; Vairo, D.; Badolato, R. STAT mutations as program switchers: Turning primary immunodeficiencies into autoimmune diseases. J. Leukoc. Biol. 2016, 101, 29–38.
  111. Kanai, T.; Jenks, J.; Nadeau, K.C. The STAT5b Pathway Defect and Autoimmunity. Front. Immunol. 2012, 3, 234.
  112. Karjalainen, A.; Shoebridge, S.; Krunic, M.; Simonović, N.; Tebb, G.; Macho-Maschler, S.; Strobl, B.; Müller, M. TYK2 in Tumor Immunosurveillance. Cancers 2020, 12, 150.
  113. Hambleton, S.; Goodbourn, S.; Young, D.F.; Dickinson, P.; Mohamad, S.M.B.; Valappil, M.; McGovern, N.; Cant, A.J.; Hackett, S.J.; Ghazal, P.; et al. STAT2 deficiency and susceptibility to viral illness in humans. Proc. Natl. Acad. Sci. 2013, 110, 3053–3058.
  114. Freij, B.J.; Hanrath, A.T.; Chen, R.; Hambleton, S.; Duncan, C.J.A. Life-Threatening Influenza, Hemophagocytic Lymphohistiocytosis and Probable Vaccine-Strain Varicella in a Novel Case of Homozygous STAT2 Deficiency. Front. Immunol. 2021, 11, 11.
  115. Schimke, L.F.; Hibbard, J.; Martinez-Barricarte, R.; Khan, T.A.; Cavalcante, R.D.S.; Junior, E.B.D.O.; França, T.T.; Iqbal, A.; Yamamoto, G.; Arslanian, C.; et al. Paracoccidioidomycosis Associated With a Heterozygous STAT4 Mutation and Impaired IFN-γ Immunity. J. Infect. Dis. 2017, 216, 1623–1634.
  116. Powell, D.A.; Shubitz, L.F.; Butkiewicz, C.D.; Moale, H.; Trinh, H.T.; Doetschman, T.; Hsu, A.P.; Holland, S.M.; Galgiani, J.N.; Frelinger, J.A. Modeling a Human STAT4 Mutation That Predisposes to Disseminated Coccidioidomycosis in Mice. J. Immunol. 2020, 204 (Suppl. 1).
  117. Okada, S.; Asano, T.; Moriya, K.; Boisson-Dupuis, S.; Kobayashi, M.; Casanova, J.-L.; Puel, A. Human STAT1 Gain-of-Function Heterozygous Mutations: Chronic Mucocutaneous Candidiasis and Type I Interferonopathy. J. Clin. Immunol. 2020, 40, 1065–1081.
  118. Kleppe, M.; Spitzer, M.H.; Li, S.; Hill, C.; Dong, L.; Papalexi, E.; De Groote, S.; Bowman, R.L.; Keller, M.; Koppikar, P.; et al. Jak1 Integrates Cytokine Sensing to Regulate Hematopoietic Stem Cell Function and Stress Hematopoiesis. Cell Stem Cell 2017, 21, 489–501.e7.
  119. Witalisz-Siepracka, A.; Klein, K.; Prinz, D.; Leidenfrost, N.; Schabbauer, G.; Dohnal, A.; Sexl, V. Loss of JAK1 Drives Innate Immune Deficiency. Front. Immunol. 2019, 9, 10.
  120. Park, S.O.; Wamsley, H.L.; Bae, K.; Hu, Z.; Li, X.; Choe, S.-W.; Slayton, W.B.; Oh, S.P.; Wagner, K.-U.; Sayeski, P.P. Conditional Deletion of Jak2 Reveals an Essential Role in Hematopoiesis throughout Mouse Ontogeny: Implications for Jak2 Inhibition in Humans. PLoS ONE 2013, 8, e59675.
  121. Betts, B.C.; Bastian, D.; Iamsawat, S.; Nguyen, H.; Heinrichs, J.L.; Wu, Y.; Daenthanasanmak, A.; Veerapathran, A.; O’Mahony, A.; Walton, K.; et al. Targeting JAK2 reduces GVHD and xenograft rejection through regulation of T cell differentiation. Proc. Natl. Acad. Sci. 2018, 115, 1582–1587.
  122. Simonović, N.; Witalisz-Siepracka, A.; Meissl, K.; Lassnig, C.; Reichart, U.; Kolbe, T.; Farlik, M.; Bock, C.; Sexl, V.; Müller, M.; et al. NK Cells Require Cell-Extrinsic and -Intrinsic TYK2 for Full Functionality in Tumor Surveillance and Antibacterial Immunity. J. Immunol. 2019, 202, 1724–1734.
  123. Prchal-Murphy, M.; Witalisz-Siepracka, A.; Bednarik, K.T.; Putz, E.M.; Gotthardt, D.; Meissl, K.; Sexl, V.; Müller, M.; Strobl, B. In vivotumor surveillance by NK cells requires TYK2 but not TYK2 kinase activity. OncoImmunology 2015, 4, e1047579.
  124. Stoiber, D.; Kovacic, B.; Schuster, C.; Schellack, C.; Karaghiosoff, M.; Kreibich, R.; Weisz, E.; Artwohl, M.; Kleine, O.C.; Muller, M.; et al. TYK2 is a key regulator of the surveillance of B lymphoid tumors. J. Clin. Investig. 2004, 114, 1650–1658.
  125. Eletto, D.; Burns, S.O.; Angulo, I.; Plagnol, V.; Gilmour, K.C.; Henriquez, F.; Curtis, J.; Gaspar, M.; Nowak, K.; Daza-Cajigal, V.; et al. Biallelic JAK1 mutations in immunodeficient patient with mycobacterial infection. Nat. Commun. 2016, 7, 13992.
  126. Rodig, S.J.; A Meraz, M.; White, J.; A Lampe, P.; Riley, J.K.; Arthur, C.D.; King, K.L.; Sheehan, K.C.; Yin, L.; Pennica, D.; et al. Disruption of the Jak1 Gene Demonstrates Obligatory and Nonredundant Roles of the Jaks in Cytokine-Induced Biologic Responses. Cell 1998, 93, 373–383.
  127. Macchi, P.; Villa, A.; Giliani, S.; Sacco, M.G.; Frattini, A.; Porta, F.; Ugazio, A.G.; Johnston, J.A.; Candotti, F.; O’Sheai, J.J.; et al. Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nat. Cell Biol. 1995, 377, 65–68.
  128. Russell, S.M.; Tayebi, N.; Nakajima, H.; Riedy, M.C.; Roberts, J.L.; Aman, M.J.; Migone, T.-S.; Noguchi, M.; Markert, M.L.; Buckley, R.H.; et al. Mutation of Jak3 in a Patient with SCID: Essential Role of Jak3 in Lymphoid Development. Science 1995, 270, 797–800.
  129. Frucht, D.M.; Gadina, M.; Jagadeesh, G.J.; Aksentijevich, I.; Takada, K.; Bleesing, J.; Nelson, J.; Muul, L.M.; Perham, G.; Morgan, G.; et al. Unexpected and variable phenotypes in a family with JAK3 deficiency. Genes Immun. 2001, 2, 422–432.
  130. Notarangelo, L.D.; Giliani, S.; Mella, P.; Schumacher, R.F.; Mazza, C.; Savoldi, G.; Rodriguez-Perez, C.; Badolato, R.; Mazzolari, E.; Porta, F.; et al. Combined Immunodeficiencies Due to Defects in Signal Transduction: Defects of the γc-JAK3 Signaling Pathway as a Model. Immunobiology 2000, 202, 106–119.
  131. Robinette, M.L.; Cella, M.; Telliez, J.B.; Ulland, T.K.; Barrow, A.D.; Capuder, K.; Gilfillan, S.; Lin, L.-L.; Notarangelo, L.D.; Colonna, M. Jak3 deficiency blocks innate lymphoid cell development. Mucosal Immunol. 2018, 11, 50–60.
  132. Baird, A.M.; Thomis, D.C.; Berg, L.J. T cell development and activation in Jak3-deficient mice. J. Leukoc. Biol. 1998, 63, 669–677.
  133. Thomis, D.C.; Gurniak, C.B.; Tivol, E.; Sharpe, A.H.; Berg, L.J. Defects in B Lymphocyte Maturation and T Lymphocyte Activation in Mice Lacking Jak3. Science 1995, 270, 794–797.
  134. Kreins, A.Y.; Ciancanelli, M.J.; Okada, S.; Kong, X.-F.; Ramírez-Alejo, N.; Kilic, S.S.; El Baghdadi, J.; Nonoyama, S.; Mahdaviani, S.A.; Ailal, F.; et al. Human TYK2 deficiency: Mycobacterial and viral infections without hyper-IgE syndrome. J. Exp. Med. 2015, 212, 1641–1662.
  135. Minegishi, Y.; Saito, M.; Morio, T.; Watanabe, K.; Agematsu, K.; Tsuchiya, S.; Takada, H.; Hara, T.; Kawamura, N.; Ariga, T.; et al. Human Tyrosine Kinase 2 Deficiency Reveals Its Requisite Roles in Multiple Cytokine Signals Involved in Innate and Acquired Immunity. Immunity 2006, 25, 745–755.
  136. Sarrafzadeh, S.A.; Mahloojirad, M.; Casanova, J.-L.; Badalzadeh, M.; Bustamante, J.; Boisson-Dupuis, S.; Pourpak, Z.; Nourizadeh, M.; Moin, M. A New Patient with Inherited TYK2 Deficiency. J. Clin. Immunol. 2020, 40, 232–235.
  137. Fuchs, S.; Kaiser-Labusch, P.; Bank, J.; Ammann, S.; Kolb-Kokocinski, A.; Edelbusch, C.; Omran, H.; Ehl, S. Tyrosine kinase 2 is not limiting human antiviral type III interferon responses. Eur. J. Immunol. 2016, 46, 2639–2649.
  138. Oyamada, A.; Ikebe, H.; Itsumi, M.; Saiwai, H.; Okada, S.; Shimoda, K.; Iwakura, Y.; Nakayama, K.I.; Iwamoto, Y.; Yoshikai, Y.; et al. Tyrosine Kinase 2 Plays Critical Roles in the Pathogenic CD4 T Cell Responses for the Development of Experimental Autoimmune Encephalomyelitis. J. Immunol. 2009, 183, 7539–7546.
  139. Chapgier, A.; Boisson-Dupuis, S.; Jouanguy, E.; Vogt, G.; Feinberg, J.; Prochnicka-Chalufour, A.; Casrouge, A.; Yang, K.; Soudais, C.; Fieschi, C.; et al. Novel STAT1 Alleles in Otherwise Healthy Patients with Mycobacterial Disease. PLoS Genet. 2006, 2, e131.
  140. Boisson-Dupuis, S.; Jouanguy, E.; Al-Hajjar, S.; Fieschi, C.; Al-Mohsen, I.Z.; Al-Jumaah, S.; Yang, K.; Chapgier, A.; Eidenschenk, C.; Eid, P.; et al. Impaired response to interferon-α/β and lethal viral disease in human STAT1 deficiency. Nat. Genet. 2003, 33, 388–391.
  141. Boisson-Dupuis, S.; Dargemont, C.; Fieschi, C.; Thomassin, N.; Rosenzweig, S.; Harris, J.; Holland, S.M.; Schreiber, R.D.; Casanova, J.-L. Impairment of Mycobacterial But Not Viral Immunity by a Germline Human STAT1 Mutation. Science 2001, 293, 300–303.
  142. Chapgier, A.; Kong, X.-F.; Boisson-Dupuis, S.; Jouanguy, E.; Averbuch, D.; Feinberg, J.; Zhang, S.-Y.; Bustamante, J.; Vogt, G.; Lejeune, J.; et al. A partial form of recessive STAT1 deficiency in humans. J. Clin. Investig. 2009, 119, 1502–1514.
  143. Lee, C.-K.; Rao, D.T.; Gertner, R.; Gimeno, R.; Frey, A.B.; Levy, D.E. Distinct Requirements for IFNs and STAT1 in NK Cell Function. J. Immunol. 2000, 165, 3571–3577.
  144. Putz, E.M.; Gotthardt, D.; Hoermann, G.; Csiszar, A.; Wirth, S.; Berger, A.; Straka, E.; Rigler, D.; Wallner, B.; Jamieson, A.; et al. CDK8-Mediated STAT1-S727 Phosphorylation Restrains NK Cell Cytotoxicity and Tumor Surveillance. Cell Rep. 2013, 4, 437–444.
  145. Semper, C.; Leitner, N.R.; Lassnig, C.; Parrini, M.; Mahlakõiv, T.; Rammerstorfer, M.; Lorenz, K.; Rigler, D.; Müller, S.; Kolbe, T.; et al. STAT1 Is Not Dominant Negative and Is Capable of Contributing to Gamma Interferon-Dependent Innate Immunity. Mol. Cell. Biol. 2014, 34, 2235–2248.
  146. Wang, X.; Zhang, R.; Wu, W.; Wang, A.; Wan, Z.; Van De Veerdonk, F.L.; Li, R. New and recurrentSTAT1mutations in seven Chinese patients with chronic mucocutaneous candidiasis. Int. J. Dermatol. 2016, 56, e30–e33.
  147. Toubiana, J.; Okada, S.; Hiller, J.; Oleastro, M.; Gomez, M.L.; Becerra, J.C.A.; Ouachã©E-Chardin, M.; Fouyssac, F.; Girisha, K.M.; Etzioni, A.; et al. Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype. Blood 2016, 127, 3154–3164.
  148. Ifrim, D.C.; Quintin, J.; Meerstein-Kessel, L.; Plantinga, T.; Joosten, L.A.B.; Van Der Meer, J.W.M.; Van De Veerdonk, F.L.; Netea, M.G. Defective trained immunity in patients with STAT-1-dependent chronic mucocutaneaous candidiasis. Clin. Exp. Immunol. 2015, 181, 434–440.
  149. Zheng, J.; Van De Veerdonk, F.L.; Crossland, K.L.; Smeekens, S.P.; Chan, C.M.; Al Shehri, T.; Abinun, M.; Gennery, A.R.; Mann, J.; Lendrem, D.W.; et al. Gain-of-function STAT1 mutations impair STAT3 activity in patients with chronic mucocutaneous candidiasis (CMC). Eur. J. Immunol. 2015, 45, 2834–2846.
  150. Tamaura, M.; Satoh-Takayama, N.; Tsumura, M.; Sasaki, T.; Goda, S.; Kageyama, T.; Hayakawa, S.; Kimura, S.; Asano, T.; Nakayama, M.; et al. Human gain-of-function STAT1 mutation disturbs IL-17 immunity in mice. Int. Immunol. 2019, 32, 259–272.
  151. Duncan, C.J.A.; Thompson, B.J.; Chen, R.; Rice, G.I.; Gothe, F.; Young, D.F.; Lovell, S.C.; Shuttleworth, V.G.; Brocklebank, V.; Corner, B.; et al. Severe type I interferonopathy and unrestrained interferon signaling due to a homozygous germline mutation inSTAT2. Sci. Immunol. 2019, 4, eaav7501.
  152. Park, C.; Li, S.; Cha, E.; Schindler, C. Immune Response in Stat2 Knockout Mice. Immunity 2000, 13, 795–804.
  153. Pelham, S.J.; Lenthall, H.C.; Deenick, E.K.; Tangye, S.G. Elucidating the effects of disease-causing mutations on STAT3 function in autosomal-dominant hyper-IgE syndrome. J. Allergy Clin. Immunol. 2016, 138, 1210–1213.e5.
  154. De Beaucoudrey, L.; Puel, A.; Filipe-Santos, O.; Cobat, A.; Ghandil, P.; Chrabieh, M.; Feinberg, J.; Von Bernuth, H.; Samarina, A.; Jannière, L.; et al. Mutations in STAT3 and IL12RB1 impair the development of human IL-17–producing T cells. J. Exp. Med. 2008, 205, 1543–1550.
  155. Takeda, K.; Noguchi, K.; Shi, W.; Tanaka, T.; Matsumoto, M.; Yoshida, N.; Kishimoto, T.; Akira, S. Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc. Natl. Acad. Sci. 1997, 94, 3801–3804.
  156. Flanagan, S.E.; Haapaniemi, E.; Russell, M.A.; Caswell, R.C.; Allen, H.L.; De Franco, E.; McDonald, T.J.; Rajala, H.L.M.; Ramelius, A.; Barton, J.; et al. Activating germline mutations in STAT3 cause early-onset multi-organ autoimmune disease. Nat. Genet. 2014, 46, 812–814.
  157. Chitnis, T.; Najafian, N.; Benou, C.; Salama, A.D.; Grusby, M.J.; Sayegh, M.H.; Khoury, S.J. Effect of targeted disruption of STAT4 and STAT6 on the induction of experimental autoimmune encephalomyelitis. J. Clin. Investig. 2001, 108, 739–747.
  158. Hwa, V.; Little, B.; Adiyaman, P.; Kofoed, E.M.; Pratt, K.L.; Ocal, G.; Berberoglu, M.; Rosenfeld, R.G. Severe Growth Hormone Insensitivity Resulting from Total Absence of Signal Transducer and Activator of Transcription 5b. J. Clin. Endocrinol. Metab. 2005, 90, 4260–4266.
  159. Kofoed, E.M.; Hwa, V.; Little, B.; Woods, K.A.; Buckway, C.K.; Tsubaki, J.; Pratt, K.L.; Bezrodnik, L.; Jasper, H.; Tepper, A.; et al. Growth Hormone Insensitivity Associated with aSTAT5bMutation. New Engl. J. Med. 2003, 349, 1139–1147.
  160. Bernasconi, A.; Marino, R.; Ribas, A.; Rossi, J.; Ciaccio, M.; Oleastro, M.; Ornani, A.; Paz, R.; Rivarola, M.A.; Zelazko, M.; et al. Characterization of Immunodeficiency in a Patient With Growth Hormone Insensitivity Secondary to a Novel STAT5b Gene Mutation. Pediatrics 2006, 118, e1584–e1592.
  161. Vargas-Hernández, A.; Witalisz-Siepracka, A.; Prchal-Murphy, M.; Klein, K.; Mahapatra, S.; Al-Herz, W.; Mace, E.M.; Carisey, A.; Orange, J.S.; Sexl, V.; et al. Human signal transducer and activator of transcription 5b (STAT5b) mutation causes dysregulated human natural killer cell maturation and impaired lytic function. J. Allergy Clin. Immunol. 2020, 145, 345–357.e9.
  162. Imada, K.; Bloom, E.T.; Nakajima, H.; Horvath-Arcidiacono, J.A.; Udy, G.B.; Davey, H.W.; Leonard, W.J. Stat5b Is Essential for Natural Killer Cell–mediated Proliferation and Cytolytic Activity. J. Exp. Med. 1998, 188, 2067–2074.
  163. Villarino, A.V.; Sciumè, G.; Davis, F.P.; Iwata, S.; Zitti, B.; Robinson, G.W.; Hennighausen, L.; Kanno, Y.; O’Shea, J.J. Subset- and tissue-defined STAT5 thresholds control homeostasis and function of innate lymphoid cells. J. Exp. Med. 2017, 214, 2999–3014.
  164. Villarino, A.; Laurence, A.; Robinson, G.W.; Bonelli, M.; Dema, B.; Afzali, B.; Shih, H.-Y.; Sun, H.-W.; Brooks, S.R.; Hennighausen, L.; et al. Signal transducer and activator of transcription 5 (STAT5) paralog dose governs T cell effector and regulatory functions. eLife 2016, 5.
  165. Quintás-Cardama, A.; Verstovsek, S. New JAK2 inhibitors for myeloproliferative neoplasms. Expert Opin. Investig. Drugs 2011, 20, 961–972.
  166. Kleppe, M.; Koche, R.; Zou, L.; van Galen, P.; Hill, C.; Dong, L.; De Groote, S.; Papalexi, E.; Somasundara, A.V.H.; Cordner, K.; et al. Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms. Cancer Cell 2018, 33, 29–43.e7.
  167. Mondet, J.; Hussein, K.; Mossuz, P. Circulating Cytokine Levels as Markers of Inflammation in Philadelphia Negative Myeloproliferative Neoplasms: Diagnostic and Prognostic Interest. Mediat. Inflamm. 2015, 2015, 1–10.
  168. Kleppe, M.; Kwak, M.; Koppikar, P.; Riester, M.; Keller, M.; Bastian, L.; Hricik, T.; Bhagwat, N.; McKenney, A.S.; Papalexi, E.; et al. JAK–STAT Pathway Activation in Malignant and Nonmalignant Cells Contributes to MPN Pathogenesis and Therapeutic Response. Cancer Discov. 2015, 5, 316–331.
  169. Przepiorka, D.; Luo, L.; Subramaniam, S.; Qiu, J.; Gudi, R.; Cunningham, L.C.; Nie, L.; Leong, R.; Ma, L.; Sheth, C.; et al. FDA Approval Summary: Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease. Oncol. 2019, 25, e328–e334.
  170. Harrison, C.N.; on Behalf of the COMFORT-II Investigators; Vannucchi, A.M.; Kiladjian, J.-J.; Al-Ali, H.K.; Gisslinger, H.; Knoops, L.; Cervantes, F.; Jones, M.M.; Sun, K.; et al. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia 2016, 30, 1701–1707.
  171. Manduzio, P. Ruxolitinib in myelofibrosis: To be or not to be an immune disruptor. Ther. Clin. Risk Manag. 2017, 13, 169–177.
  172. Tremblay, D.; King, A.; Li, L.; Moshier, E.; Coltoff, A.; Koshy, A.; Kremyanskaya, M.; Hoffman, R.; Mauro, M.J.; Rampal, R.K.; et al. Risk factors for infections and secondary malignancies in patients with a myeloproliferative neoplasm treated with ruxolitinib: A dual-center, propensity score-matched analysis. Leuk. Lymphoma 2019, 61, 660–667.
  173. Porpaczy, E.; Tripolt, S.; Hoelbl-Kovacic, A.; Gisslinger, B.; Bago-Horvath, Z.; Casanova-Hevia, E.; Clappier, E.; Decker, T.; Fajmann, S.; Fux, D.A.; et al. Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy. Blood 2018, 132, 694–706.
  174. Rumi, E.; Zibellini, S.; Boveri, E.; Cavalloni, C.; Riboni, R.; Casetti, I.C.; Ciboddo, M.; Trotti, C.; Favaron, C.; Pietra, D.; et al. Ruxolitinib treatment and risk of B-cell lymphomas in myeloproliferative neoplasms. Am. J. Hematol. 2019, 94, E185–E188.
  175. Mora, B.; Rumi, E.; Guglielmelli, P.; Barraco, D.; Maffioli, M.; Rambaldi, A.; Caramella, M.; Komrokji, R.; Gotlib, J.; Kiladjian, J.J.; et al. Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients. Cancer Med. 2019, 8, 4089–4092.
  176. Maffioli, M.; Giorgino, T.; Mora, B.; Iurlo, A.; Elli, E.; Finazzi, M.C.; Caramella, M.; Rumi, E.; Carraro, M.C.; Polverelli, N.; et al. Second primary malignancies in ruxolitinib-treated myelofibrosis: Real-world evidence from 219 consecutive patients. Blood Adv. 2019, 3, 3196–3200.
  177. Smolen, J.S.; Genovese, M.C.; Takeuchi, T.; Hyslop, D.L.; Macias, W.L.; Rooney, T.; Chen, L.; Dickson, C.L.; Camp, J.R.; Cardillo, T.E.; et al. Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment. J. Rheumatol. 2018, 46, 7–18.
  178. Schönberg, K.; Rudolph, J.; Vonnahme, M.; Yajnanarayana, S.P.; Cornez, I.; Hejazi, M.; Manser, A.R.; Uhrberg, M.; Verbeek, W.; Koschmieder, S.; et al. JAK Inhibition Impairs NK Cell Function in Myeloproliferative Neoplasms. Cancer Res. 2015, 75, 2187–2199.
  179. Curran, S.A.; Shyer, J.A.; Angelo, E.T.S.; Talbot, L.R.; Sharma, S.; Chung, D.J.; Heller, G.; Hsu, K.C.; Betts, B.C.; Young, J.W. Human Dendritic Cells Mitigate NK-Cell Dysfunction Mediated by Nonselective JAK1/2 Blockade. Cancer Immunol. Res. 2017, 5, 52–60.
  180. Lucas, M.; Schachterle, W.; Oberle, K.; Aichele, P.; Diefenbach, A. Dendritic Cells Prime Natural Killer Cells by trans-Presenting Interleukin 15. Immunity 2007, 26, 503–517.
  181. Heine, A.; Held, S.A.E.; Daecke, S.N.; Wallner, S.; Yajnanarayana, S.P.; Kurts, C.; Wolf, D.; Brossart, P. The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo. Blood 2013, 122, 1192–1202.
  182. Rudolph, J.; Heine, A.; Quast, T.; Kolanus, W.; Trebicka, J.; Brossart, P.; Wolf, D. The JAK inhibitor ruxolitinib impairs dendritic cell migration via off-target inhibition of ROCK. Leukemia 2016, 30, 2119–2123.
  183. Yajnanarayana, S.P.; Stübig, T.; Cornez, I.; Alchalby, H.; Schönberg, K.; Rudolph, J.; Triviai, I.; Wolschke, C.; Heine, A.; Brossart, P.; et al. JAK1/2 inhibition impairs T cell functionin vitroand in patients with myeloproliferative neoplasms. Br. J. Haematol. 2015, 169, 824–833.
  184. Keohane, C.; Kordasti, S.Y.; Seidl, T.; Abellan, P.P.; Thomas, N.S.B.; Harrison, C.N.; McLornan, D.P.; Mufti, G.J. JAK inhibition induces silencing of T Helper cytokine secretion and a profound reduction in T regulatory cells. Br. J. Haematol. 2015, 171, 60–73.
  185. Massa, M.L.; Rosti, V.; Campanelli, R.; Fois, G.; Barosi, G. Rapid and long-lasting decrease of T-regulatory cells in patients with myelofibrosis treated with ruxolitinib. Leukemia 2014, 28, 449–451.
  186. Spoerl, S.; Mathew, N.R.; Bscheider, M.; Schmitt-Graeff, A.; Chen, S.; Mueller, T.; Verbeek, M.; Fischer, J.; Otten, V.; Schmickl, M.; et al. Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease. Blood 2014, 123, 3832–3842.
  187. Sørensen, A.L.; Bjørn, M.E.; Riley, C.H.; Holmstrøm, M.; Andersen, M.H.; Svane, I.M.; Mikkelsen, S.U.; Skov, V.; Kjaer, L.; Hasselbalch, H.C.; et al. B-cell frequencies and immunoregulatory phenotypes in myeloproliferative neoplasms: Influence of ruxolitinib, interferon-α2, or combination treatment. Eur. J. Haematol. 2019, 103, 351–361.
  188. Fleischmann, R.; Kremer, J.; Cush, J.; Schulze-Koops, H.; Connell, C.A.; Bradley, J.D.; Gruben, D.; Wallenstein, G.V.; Zwillich, S.H.; Kanik, K.S. Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis. New Engl. J. Med. 2012, 367, 495–507.
  189. Kontzias, A.; Kotlyar, A.; Laurence, A.; Changelian, P.; O’Shea, J.J. Jakinibs: A new class of kinase inhibitors in cancer and autoimmune disease. Curr. Opin. Pharmacol. 2012, 12, 464–470.
  190. Degryse, S.; Cools, J. JAK kinase inhibitors for the treatment of acute lymphoblastic leukemia. J. Hematol. Oncol. 2015, 8, 1–5.
  191. Ghoreschi, K.; Jesson, M.I.; Li, X.; Lee, J.L.; Ghosh, S.; Alsup, J.W.; Warner, J.D.; Tanaka, M.; Steward-Tharp, S.M.; Gadina, M.; et al. Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550). J. Immunol. 2011, 186, 4234–4243.
  192. Migita, K.; Miyashita, T.; Izumi, Y.; Koga, T.; Komori, A.; Maeda, Y.; Jiuchi, Y.; Aiba, Y.; Yamasaki, S.; Kawakami, A.; et al. Inhibitory effects of the JAK inhibitor CP690,550 on human CD4+ T lymphocyte cytokine production. BMC Immunol. 2011, 12, 51.
  193. Sonomoto, K.; Yamaoka, K.; Kubo, S.; Hirata, S.; Fukuyo, S.; Maeshima, K.; Suzuki, K.; Saito, K.; Tanaka, Y. Effects of tofacitinib on lymphocytes in rheumatoid arthritis: Relation to efficacy and infectious adverse events. Rheumatology 2014, 53, 914–918.
  194. A Hodge, J.; Kawabata, T.T.; Krishnaswami, S.; Clark, J.D.; Telliez, J.-B.; E Dowty, M.; Menon, S.; Lamba, M.; Zwillich, S. The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Clin. Exp. Rheumatol. 2016, 34, 318–328.
  195. Conklyn, M.; Andresen, C.; Changelian, P.; Kudlacz, E. The JAK3 inhibitor CP-690550 selectively reduces NK and CD8+ cell numbers in cynomolgus monkey blood following chronic oral dosing. J. Leukoc. Biol. 2004, 76, 1248–1255.
  196. Kudlacz, E.; Perry, B.; Sawyer, P.; Conklyn, M.; McCurdy, S.; Brissette, W.; And, M.F.; Changelian, P. The Novel JAK-3 Inhibitor CP-690550 Is a Potent Immunosuppressive Agent in Various Murine Models. Arab. Archaeol. Epigr. 2004, 4, 51–57.
  197. Shimaoka, H.; Takeno, S.; Maki, K.; Sasaki, T.; Hasegawa, S.; Yamashita, Y. A cytokine signal inhibitor for rheumatoid arthritis enhances cancer metastasis via depletion of NK cells in an experimental lung metastasis mouse model of colon cancer. Oncol. Lett. 2017, 14, 3019–3027.
  198. Vian, L.; Le, M.T.; Gazaniga, N.; Kieltyka, J.; Liu, C.; Pietropaolo, G.; Dell’Orso, S.; Brooks, S.R.; Furumoto, Y.; Thomas, C.J.; et al. JAK Inhibition Differentially Affects NK Cell and ILC1 Homeostasis. Front. Immunol. 2019, 10, 2972.
  199. Rochman, Y.; Spolski, R.; Leonard, W.J. New insights into the regulation of T cells by γc family cytokines. Nat. Rev. Immunol. 2009, 9, 480–490.
  200. Meazza, R.; Azzarone, B.; Orengo, A.M.; Ferrini, S. Role of Common-Gamma Chain Cytokines in NK Cell Development and Function: Perspectives for Immunotherapy. J. Biomed. Biotechnol. 2011, 2011, 1–16.
  201. Marçais, A.; Viel, S.; Grau, M.; Henry, T.; Marvel, J.; Walzer, T. Regulation of Mouse NK Cell Development and Function by Cytokines. Front. Immunol. 2013, 4, 450.
  202. Changelian, P.S.; Flanagan, M.E.; Ball, D.J.; Kent, C.R.; Magnuson, K.S.; Martin, W.H.; Rizzuti, B.J.; Sawyer, P.S.; Perry, B.D.; Brissette, W.H.; et al. Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor. Science 2003, 302, 875–878.
  203. Van Vollenhoven, R.; Tanaka, Y.; Lamba, M.; Collinge, M.; Hendrikx, T.; Hirose, T.; Toyoizumi, S.; Hazra, A.; Krishnaswami, S. THU0178 Relationship Between NK Cell Count and Important Safety Events in Rheumatoid Arthritis Patients Treated with Tofacitinib. Ann. Rheum. Dis. 2015, 74, 258.3–259.
  204. Van Vollenhoven, R.; Choy, E.; Lee, E.; Hazra, A.; Anisfeld, A.; Lazariciu, I.; Biswas, P.; Lamba, M.; Menon, S.; Hodge, J.; et al. THU0199 Tofacitinib, An Oral Janus Kinase Inhibitor, in The Treatment of Rheumatoid Arthritis: Changes in Lymphocytes and Lymphocyte Subset Counts and Reversibility after Up To 8 Years of Tofacitinib Treatment. Ann. Rheum. Dis. 2016, 75, 258.
  205. Van Vollenhoven, R.; Lee, E.B.; Strengholt, S.; Mojcik, C.; Valdez, H.; Krishnaswami, S.; Biswas, P.; Lazariciu, I.; Hazra, A.; Clark, J.D.; et al. Evaluation of the Short-, Mid-, and Long-Term Effects of Tofacitinib on Lymphocytes in Patients With Rheumatoid Arthritis. Arthritis Rheumatol. 2019, 71, 685–695.
  206. Weinhold, K.J.; Bukowski, J.F.; Brennan, T.V.; Noveck, R.J.; Staats, J.S.; Lin, L.; Stempora, L.; Hammond, C.; Wouters, A.; Mojcik, C.F.; et al. Reversibility of peripheral blood leukocyte phenotypic and functional changes after exposure to and withdrawal from tofacitinib, a Janus kinase inhibitor, in healthy volunteers. Clin. Immunol. 2018, 191, 10–20.
  207. Angelini, J.; Talotta, R.; Roncato, R.; Fornasier, G.; Barbiero, G.; Cin, L.D.; Brancati, S.; Scaglione, F. JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future. Biomolecules 2020, 10, 1002.
  208. Nocturne, G.; Pascaud, J.; Ly, B.; Tahmasebi, F.; Mariette, X. JAK inhibitors alter NK cell functions and may impair immunosurveillance against lymphomagenesis. Cell. Mol. Immunol. 2020, 17, 552–553.
  209. Kubo, S.; Yamaoka, K.; Kondo, M.; Yamagata, K.; Zhao, J.; Iwata, S.; Tanaka, Y. The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells. Ann. Rheum. Dis. 2013, 73, 2192–2198.
  210. Sewgobind, V.D.K.D.; Quaedackers, M.E.; Van Der Laan, L.J.W.; Kraaijeveld, R.; Korevaar, S.S.; Chan, G.; Weimar, W.; Baan, C.C. The Jak Inhibitor CP-690,550 Preserves the Function of CD4+CD25brightFoxP3+ Regulatory T Cells and Inhibits Effector T Cells. Arab. Archaeol. Epigr. 2010, 10, 1785–1795.
  211. Meyer, A.; Wittekind, P.S.; Kotschenreuther, K.; Schiller, J.; Von Tresckow, J.; Haak, T.H.; Kofler, D.M. Regulatory T cell frequencies in patients with rheumatoid arthritis are increased by conventional and biological DMARDs but not by JAK inhibitors. Ann. Rheum. Dis. 2019.
  212. Rizzi, M.; Lorenzetti, R.; Fischer, K.; Staniek, J.; Janowska, I.; Troilo, A.; Strohmeier, V.; Erlacher, M.; Kunze, M.; Bannert, B.; et al. Impact of tofacitinib treatment on human B-cells in vitro and in vivo. J. Autoimmun. 2017, 77, 55–66.
  213. Mariette, X.; Chen, C.; Biswas, P.; Kwok, K.; Boy, M.G. Lymphoma in the Tofacitinib Rheumatoid Arthritis Clinical Development Program. Arthritis Rheum. 2018, 70, 685–694.
  214. PFIZER press release. Available online: (accessed on 1 April 2021).
  215. Talpaz, M.; Kiladjian, J.-J. Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis. Leukemia 2021, 35, 1–17.
  216. Kim, W.S.; Kim, M.J.; Kim, D.O.; Byun, J.-E.; Huy, H.; Song, H.Y.; Park, Y.-J.; Kim, T.-D.; Yoon, S.R.; Choi, E.-J.; et al. Suppressor of Cytokine Signaling 2 Negatively Regulates NK Cell Differentiation by Inhibiting JAK2 Activity. Sci. Rep. 2017, 7, 46153.
  217. Betts, B.C.; Abdel-Wahab, O.; Curran, S.A.; Angelo, E.T.S.; Koppikar, P.; Heller, G.; Levine, R.L.; Young, J.W. Janus kinase-2 inhibition induces durable tolerance to alloantigen by human dendritic cell–stimulated T cells yet preserves immunity to recall antigen. Blood 2011, 118, 5330–5339.
  218. Mesa, R.A.; Kiladjian, J.-J.; Catalano, J.V.; Devos, T.; Egyed, M.; Hellmann, A.; McLornan, D.; Shimoda, K.; Winton, E.F.; Deng, W.; et al. SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor–Naïve Patients With Myelofibrosis. J. Clin. Oncol. 2017, 35, 3844–3850.
  219. Patel, A.A.; Odenike, O. The Next Generation of JAK Inhibitors: An Update on Fedratinib, Momelotonib, and Pacritinib. Curr. Hematol. Malign- Rep. 2020, 15, 409–418.
  220. Singer, J.W.; Al-Fayoumi, S.; Taylor, J.; Velichko, S.; O’Mahony, A. Comparative phenotypic profiling of the JAK2 inhibitors ruxolitinib, fedratinib, momelotinib, and pacritinib reveals distinct mechanistic signatures. PLoS ONE 2019, 14, e0222944.
  221. Singer, J.W.; Al-Fayoumi, S.; Ma, H.; Komrokji, R.S.; Mesa, R.; Verstovsek, S. Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor. J. Exp. Pharmacol. 2016, ume 8, 11–19.
  222. Hosseini, M.M.; Kurtz, S.E.; Abdelhamed, S.; Mahmood, S.; Davare, M.A.; Kaempf, A.; Elferich, J.; McDermott, J.E.; Liu, T.; Payne, S.H.; et al. Inhibition of interleukin-1 receptor-associated kinase-1 is a therapeutic strategy for acute myeloid leukemia subtypes. Leukemia 2018, 32, 2374–2387.
  223. Pidala, J.; Walton, K.; Elmariah, H.; Kim, J.; Mishra, A.; Bejanyan, N.; Nishihori, T.; Khimani, F.; Perez, L.; Faramand, R.G.; et al. Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results. Clin. Cancer Res. 2021, 27, 2712–2722.
  224. Covington, M.; He, X.; Scuron, M.; Li, J.; Collins, R.; Juvekar, A.; Shin, N.; Favata, M.; Gallagher, K.; Sarah, S.; et al. Preclinical characterization of itacitinib (INCB039110), a novel selective inhibitor of JAK1, for the treatment of inflammatory diseases. Eur. J. Pharmacol. 2020, 885, 173505.
  225. Murray, P.J. The JAK-STAT Signaling Pathway: Input and Output Integration. J. Immunol. 2007, 178, 2623–2629.
  226. Huarte, E.; O’Connor, R.S.; Peel, M.T.; Nunez-Cruz, S.; Leferovich, J.; Juvekar, A.; Yang, Y.-O.; Truong, L.; Huang, T.; Naim, A.; et al. Itacitinib (INCB039110), a JAK1 Inhibitor, Reduces Cytokines Associated with Cytokine Release Syndrome Induced by CAR T-cell Therapy. Clin. Cancer Res. 2020, 26, 6299–6309.
  227. Juvekar, A.; Ruggeri, B.; Condon, S.; Borkowski, A.; Huber, R.; Smith, P. Itacitinib, a JAK1 Selective Inhibitor Preserves Graft-Versus-Leukemia (GVL), Enhances Survival and Is Highly Efficacious in a MHC-Mismatched Mouse Model of Acute GvHD. Blood 2018, 132, 4522.
  228. Schroeder, M.A.; Khoury, H.J.; Jagasia, M.; Ali, H.; Schiller, G.J.; Staser, K.; Choi, J.; Gehrs, L.; Arbushites, M.C.; Yan, Y.; et al. A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease. Blood Adv. 2020, 4, 1656–1669.
  229. Luchi, M.; Fidelus-Gort, R.; Douglas, D.; Zhang, H.; Flores, R.; Newton, R.; Scherle, P.; Yeleswaram, S.; Chen, X.; Sandor, V.A. Randomized, Dose-Ranging, Placebo-Controlled, 84-Day Study Of INCB039110, a Selective Janus Kinase-1 Inhibitor, In Pa-tients With Active Rheumatoid Arthritis - ACR Meeting Abstracts. Arthritis Rheum 2013, 65 (Suppl. 10), 1797.
  230. Norman, P. Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin. Investig. Drugs 2014, 23, 1067–1077.
  231. Bissonnette, R.; Luchi, M.; Fidelus-Gort, R.; Jackson, S.; Zhang, H.; Flores, R.; Newton, R.; Scherle, P.; Yeleswaram, S.; Chen, X.; et al. A randomized, double-blind, placebo-controlled, dose-escalation study of the safety and efficacy of INCB039110, an oral janus kinase 1 inhibitor, in patients with stable, chronic plaque psoriasis. J. Dermatol. Treat. 2015, 27, 332–338.
  232. Banerjee, S.; Biehl, A.; Gadina, M.; Hasni, S.; Schwartz, D.M. JAK–STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects. Drugs 2017, 77, 521–546.
  233. Zhang, M.; Griner, L.A.M.; Ju, W.; Duveau, D.Y.; Guha, R.; Petrus, M.N.; Wen, B.; Maeda, M.; Shinn, P.; Ferrer, M.; et al. Selective targeting of JAK/STAT signaling is potentiated by Bcl-xL blockade in IL-2–dependent adult T-cell leukemia. Proc. Natl. Acad. Sci. 2015, 112, 12480–12485.
  234. Waldmann, T.A. JAK/STAT pathway directed therapy of T-cell leukemia/lymphoma: Inspired by functional and structural genomics. Mol. Cell. Endocrinol. 2017, 451, 66–70.
  235. Senkevitch, E.; Li, W.; Hixon, J.A.; Andrews, C.; Cramer, S.D.; Pauly, G.; Back, T.; Czarra, K.; Durum, S.K. Inhibiting Janus Kinase 1 and BCL-2 to treat T cell acute lymphoblastic leukemia with IL7-Rα mutations. Oncotarget 2018, 9, 22605–22617.
  236. Shouse, G.; Nikolaenko, L. Targeting the JAK/STAT Pathway in T Cell Lymphoproliferative Disorders. Curr. Hematol. Malign- Rep. 2019, 14, 570–576.
  237. Hee, Y.T.; Yan, J.; Nizetic, D.; Chng, W.-J. LEE011 and ruxolitinib: A synergistic drug combination for natural killer/T-cell lymphoma (NKTCL). Oncotarget 2018, 9, 31832–31841.
  238. Mondéjar, R.; Pérez, C.; Onaindía, A.; Martínez, N.; González-Rincón, J.; Pisonero, H.; Vaque, J.P.; Cereceda, L.; Santibañez, M.; Sánchez-Beato, M.; et al. Molecular basis of targeted therapy in T/NK-cell lymphoma/leukemia: A comprehensive genomic and immunohistochemical analysis of a panel of 33 cell lines. PLoS ONE 2017, 12, e0177524.
  239. Neste, E.V.D.; André, M.; Gastinne, T.; Stamatoullas, A.; Haioun, C.; Belhabri, A.; Reman, O.; Casasnovas, O.; Ghesquieres, H.; Verhoef, G.; et al. A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma. Haematologica 2018, 103, 840–848.
  240. Moskowitz, A.J.; Ghione, P.; Jacobsen, E.D.; Ruan, J.; Schatz, J.H.; Noor, S.; Myskowski, P.; Hancock, A.H.; Davey, M.T.; Obadi, O.; et al. Final Results of a Phase II Biomarker-Driven Study of Ruxolitinib in Relapsed and Refractory T-Cell Lymphoma. Blood 2019, 134, 4019.
  241. Mulvey, E.; Ruan, J. Biomarker-driven management strategies for peripheral T cell lymphoma. J. Hematol. Oncol. 2020, 13, 1–20.
  242. Karagianni, F.; Piperi, C.; Mpakou, V.; Spathis, A.; Foukas, P.G.; Dalamaga, M.; Pappa, V.; Papadavid, E. Ruxolitinib with resminostat exert synergistic antitumor effects in Cutaneous T-cell Lymphoma. PLoS ONE 2021, 16, e0248298.
  243. Braun, T.; Von Jan, J.; Wahnschaffe, L.; Herling, M. Advances and Perspectives in the Treatment of T-PLL. Curr. Hematol. Malign- Rep. 2020, 15, 113–124.
  244. Ando, S.; Kawada, J.-I.; Watanabe, T.; Suzuki, M.; Sato, Y.; Torii, Y.; Asai, M.; Goshima, F.; Murata, T.; Shimizu, N.; et al. Tofacitinib induces G1 cell-cycle arrest and inhibits tumor growth in Epstein-Barr virus-associated T and natural killer cell lymphoma cells. Oncotarget 2016, 7, 76793–76805.
  245. Wei, B.M.; Koshy, N.; Van Besien, K.; Inghirami, G.; Horwitz, S.M. Refractory T-Cell Prolymphocytic Leukemia with JAK3 Mutation: In Vitro and Clinical Synergy of Tofacitinib and Ruxolitinib. Blood 2015, 126, 5486.
  246. Gomez-Arteaga, A.; Margolskee, E.; Wei, M.T.; Van Besien, K.; Inghirami, G.; Horwitz, S. Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation. Leuk. Lymphoma 2019, 60, 1626–1631.
  247. Lindahl, L.M.; Fredholm, S.; Joseph, C.; Nielsen, B.S.; Jønson, L.; Willerslev-Olsen, A.; Gluud, M.; Blümel, E.; Petersen, D.L.; Sibbesen, N.; et al. STAT5 induces miR-21 expression in cutaneous T cell lymphoma. Oncotarget 2016, 7, 45730–45744.
  248. Cabannes, A.; Schmidt, A.; Brissot, E.; Balsat, M.; Maury, S.; Isnard, F.; Chevallier, P.; Cacheux, V.; Cluzeau, T.; Graux, C.; et al. The Combination of Venetoclax and Tofacitinib Induced Hematological Responses in Patients with Relapse/ Refractory T-ALL with BCL2 Expression and Surface IL7R Expression or IL7R-Pathway Mutations (On behalf of the GRAALL). Blood 2019, 134, 1339.
  249. Wong, J.; Wall, M.; Corboy, G.P.; Taubenheim, N.; Gregory, G.P.; Opat, S.; Shortt, J. Failure of tofacitinib to achieve an objective response in a DDX3X-MLLT10 T-lymphoblastic leukemia with activating JAK3 mutations. Mol. Case Stud. 2020, 6, a004994.
  250. Zhang, R.; Shah, M.V.; Loughran, T.P. The root of many evils: Indolent large granular lymphocyte leukaemia and associated disorders. Hematol. Oncol. 2009, 28, 105–117.
  251. Lamy, T.; Loughran, J.T.P. How I treat LGL leukemia. Blood 2011, 117, 2764–2774.
  252. Shah, M.V.; Hook, C.C.; Call, T.G.; Go, R.S. A population-based study of large granular lymphocyte leukemia. Blood Cancer J. 2016, 6, e455.
  253. Lamy, T.; Moignet, A.; Loughran, T.P. LGL leukemia: From pathogenesis to treatment. Blood 2017, 129, 1082–1094.
  254. Firestein, G.S. Evolving concepts of rheumatoid arthritis. Nat. Cell Biol. 2003, 423, 356–361.
  255. Liu, X.; Loughran, T.P. The spectrum of large granular lymphocyte leukemia and Feltyʼs syndrome. Curr. Opin. Hematol. 2011, 18, 254–259.
  256. Bockorny, B.; Dasanu, C.A. Autoimmune Manifestations in Large Granular Lymphocyte Leukemia. Clin. Lymphoma Myeloma Leuk. 2012, 12, 400–405.
  257. Poullot, E.; Zambello, R.; Leblanc, F.; Bareau, B.; De March, E.; Roussel, M.; Boulland, M.L.; Houot, R.; Renault, A.; Fest, T.; et al. Chronic natural killer lymphoproliferative disorders: Characteristics of an international cohort of 70 patients. Ann. Oncol. 2014, 25, 2030–2035.
  258. Moignet, A.; Lamy, T. Latest Advances in the Diagnosis and Treatment of Large Granular Lymphocytic Leukemia. Am. Soc. Clin. Oncol. Educ. Book 2018, 38, 616–625.
More
ScholarVision Creations